by Christina Black | Jun 19, 2020View the published article
Follow Us on Twitter
Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek
This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
Sunday, June 5, 8-11:00 AM CDT
June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT
June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT